Klaus Wagner

Klaus Wagner serves as the Chief Medical Officer at Neomorph, Inc. since January 2025, following a tenure as Chief Medical Officer at Boundless Bio, Inc. from January 2022 to December 2024, focusing on the clinical development of small molecule inhibitors. Prior to that role, Klaus held the position of EVP Chief Medical Officer at Inhibrx Biosciences, Inc. from January 2015 to December 2022, concentrating on the development of single domain (VHH) based multivalent and/or multispecific antibodies. Klaus's experience also includes working as a Medical Oncologist at MD Anderson Cancer Center (Banner) from January 2012 to December 2015, specializing in thoracic and head & neck oncology with an emphasis on cancer immunotherapies and molecular targeted therapies. Early career experience includes a role at Genentech during 2011-2012. Klaus Wagner holds an MD and a PhD from medical school.